RefloDx raises $2M seed to build wearable reflux test
What's the deal? Utah medical device company RefloDxDealroom has a profile for this one. Try Dealroom → has closed a $2 million seed round to develop and validate SondeFlux, a noninvasive wearable ultrasound device that detects stomach contents refluxing into the upper esophagus. The round drew Crocker VenturesDealroom has a profile for this one. Try Dealroom →, Wild Tree VenturesDealroom has a profile for this one. Try Dealroom →, Convoi VenturesDealroom has a profile for this one. Try Dealroom →, Nucleus Fund, Park City AngelsDealroom has a profile for this one. Try Dealroom →, and TransAtlantic Angels, alongside individual investors.
What's the endgame? RefloDx wants to give physicians objective evidence of upper-esophageal reflux without invasive testing. Proceeds will fund device and algorithm development and a multi-center, blinded validation study.
Why now? An estimated 15 to 25 million people in the US each year see a doctor for chronic cough, hoarseness, throat clearing, or difficulty swallowing. Clinical consensus now recommends objective evidence of reflux before starting long-term drug treatment — but current catheter-based testing reaches fewer than 5% of patients.
As a result, most patients are treated on presumption with medication. "Millions of patients with chronic throat and voice symptoms can't get objective reflux test results today, so most are treated on a presumption," said chair and chief executive officer Gregory Critchfield. The estimated 2026 US cost to work up symptoms and treat laryngopharyngeal reflux is $70 billion.
What could go wrong? The device is still in development. RefloDx expects blinded validation data in 2027; success is meant to support a future FDA submission, reimbursement codes, and eventual commercial launch — none of which is guaranteed.
The signal: RefloDx is betting that noninvasive, at-home diagnostics can displace poorly tolerated hospital procedures and cut wasteful spending. The $2 million seed sits around the 34th percentile for its size — modest capital to carry a medical device company toward clinical proof.
Read more: utahbusiness.com
Image credit: Generated with Gemini
